1. Journal Papers

This table browses all dspace content
Issue DateTitleJournal Title
2025Proportion of histologic component predicts lymph node metastasis risk in undifferentiated-type mucosal and submucosal gastric cancersVIRCHOWS ARCHIV
2025Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21) BMC CANCER
2025Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 TrialCIRCULATION
2025Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study JOURNAL FOR IMMUNOTHERAPY OF CANCER
2025A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19 NATURE COMMUNICATIONS
2025Utility of Non-HLA Autoantibodies in Predicting Graft Survival After Heart TransplantationTRANSPLANTATION
2025Machine learning prediction of in-hospital mortality and external validation in patients with cardiogenic shock: the RESCUE scoreREVISTA ESPANOLA DE CARDIOLOGIA
2025Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver diseaseJOURNAL OF HEPATOLOGY
2025Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study ANNALS OF ONCOLOGY
2025Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study EUROPEAN JOURNAL OF CANCER
2025Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumabOSTEOPOROSIS INTERNATIONAL
2025Evolving roles of MET as a therapeutic target in NSCLC and beyondNATURE REVIEWS CLINICAL ONCOLOGY
2025Clinical Characteristics and Management of Statin-Associated Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy JOURNAL OF CLINICAL MEDICINE
2025An Artificial Intelligence-Enabled Electrocardiogram to Evaluate Patients With Dyspnea in the Emergency Department MAYO CLINIC PROCEEDINGS-INNOVATIONS QUALITY & OUTCOMES
2025BP and Kidney Disease Progression in Advanced CKD Findings from the Chronic Renal Insufficiency Cohort and KoreaN Cohort Study for Outcome in Patients with CKD StudiesCLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
2025Epidemiology of osteoporotic ankle fractures in South Korea: a nationwide retrospective cohort study (2006-2022)OSTEOPOROSIS INTERNATIONAL
2025FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma CANCER TREATMENT REVIEWS
2025Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort CANCER
2025Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study JOURNAL OF CLINICAL ONCOLOGY
2025Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 studyLANCET ONCOLOGY

Recent Submissions

Browse

Links